BioLineRx (BLRX) In-Licenses Novel Treatment for Liver Failure Conditions
BioLineRx Ltd. (NASDAQ/TASE: BLRX) this morning said it has entered into an exclusive, worldwide agreement with BGN Technologies, the Technology Transfer Company of Ben-Gurion University, and Hadasit, the Technology Transfer Company of Hadassah Medical Organization, regarding the in-licensing of BL-1220 for the treatment of liver pathologies. BL-1220 marks BioLineRx’s second project in-licensed under its collaboration with Novartis Pharma AG (NYSE: NVS) for the screening and development of novel drug candidates. "In August this year, we in-licensed the first compound under our multi-year strategic partnership with Novartis … Today, we are pleased to announce the second compound under the Novartis collaboration…







